| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
| Products Intro: |
Product Name:MCC-555
CAS:161600-01-7
Purity:>=98% (HPLC) Package:25MG Remarks:SML0896-25MG
|
|
| | MCC-555 Basic information |
| Product Name: | MCC-555 | | Synonyms: | MCC-555;NETOGLITAZONE,2,4-THIAZOLIDINEDIONE, 5-[[6-[(2-FLUOROPHENYL)METHOXY]-2-NAPHTHALENYL]METHYL]-;Isaglitazone;Netoglitazone;RWJ 241947;5-[[6-[(2-FLUOROPHENYL)METHOXY]-2-NAPHTHALENYL]METHYL]-2,4-THIAZOLIDINEDIONE;5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione;5-((6-((2-Fluorobenzyl)oxy)naphthalen-2-yl)methyl)thiazolidine-2,4-dione | | CAS: | 161600-01-7 | | MF: | C21H16FNO3S | | MW: | 381.42 | | EINECS: | | | Product Categories: | | | Mol File: | 161600-01-7.mol |  |
| | MCC-555 Chemical Properties |
| Boiling point | 599.5±30.0 °C(Predicted) | | density | 1.369±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: soluble10mg/mL, clear | | pka | 6.28±0.50(Predicted) | | form | powder | | color | white to beige |
| Hazard Codes | N | | Risk Statements | 50/53 | | Safety Statements | 60-61 | | RIDADR | UN 3077 9 / PGIII | | WGK Germany | 3 | | RTECS | XJ5813445 |
| | MCC-555 Usage And Synthesis |
| Uses | MCC 555 belongs to the thiazolidinedion class, a group of compounds with anti-diabetic properties. In addition, MCC 555 has been found to induce apoptosis in pancreatic and colorectal cancer cells involving the?Nonsteroidal anti-inflammatory drug (NSAID)-activated gene?(NAG-1). MCC 555 is an agent with anti-diabetic and anti-cancer properties. | | Uses | Antidiabetic; orally-administered insulin action enhancer to lower the plasma glucose in patients with non-insulin dependent diabetes mellitus (Type II). | | Biological Activity | mcc-555, also known as rwj-241947, is a novel peroxisome proliferator–activated receptor γ ligand [1].the pparγ receptors mainly express in adipose tissue, colon and macrophages involved in regulating fatty acid storage and glucose metabolism. it has been identified that pparγ is the major functional receptor for the thiazolidinedione class of insulin-sensitizing drugs. the pparγ receptor is implicated in the processes of adipogenesis and systemic insulin action [2].mcc-555 (5 μmol/l) exhibited an apoptotic activity in human colorectal cancer cells. mcc-555 significantly increased nag-1 expression in a pparγ-independent manner. in hct-116 cells, treatment with mcc-555 induced apoptosis. mcc-555 affected nag-1 mrna stability. mcc-555 treatment induced rapid phosphorylation of erk1/2 [1]. in various solid and hematological tumor cell lines, mcc-555 showed antiproliferative activity against prostate cancer cells, with the strongest effect against the androgen-independent pc-3 prostate cancer cells [2].in male beige/nude/x-linked immunodeficient (bnx) mice, treatment with mcc-555 profoundly suppressed growth of pc-3 prostate cancer xenografts with prominent apoptosis, fibrosis, and inflammatory and giant cell reaction. the experimented mice showed significantly decreased cholesterol [3]. | | Biochem/physiol Actions | MCC-555 is a thiazolidinedione class anti-diabetic compound. In rodent models, MCC-555 attenuates the development of diabetes, maintains B-cell function and improves insulin sensitivity. The compound MCC-555 also inhibits proliferation of several cancer cell lines and reduces tumor growth in xenograft models. | | references | [1] yamaguchi k, lee s h, eling t e, et al. a novel peroxisome proliferator–activated receptor γ ligand, mcc-555, induces apoptosis via posttranscriptional regulation of nag-1 in colorectal cancer cells[j]. molecular cancer therapeutics, 2006, 5(5): 1352-1361.
[2] spiegelman b m. ppar-gamma: adipogenic regulator and thiazolidinedione receptor[j]. diabetes, 1998, 47(4): 507-514.
[3] kumagai t, ikezoe t, gui d, et al. rwj-241947 (mcc-555), a unique peroxisome proliferator-activated receptor-γ ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/x-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide[j]. clinical cancer research, 2004, 10(4): 1508-1520. |
| | MCC-555 Preparation Products And Raw materials |
|